Please ensure Javascript is enabled for purposes of website accessibility

Is GlaxoSmithKline plc's Monster Dividend Worth the Risk?

By George Budwell - Dec 30, 2014 at 7:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GlaxoSmithKline has had a rotten 2014, leading to a dramatic downturn in its share price. Can this high-yielding dividend stock rebound in 2015?

Source: GlaxoSmithKline 

British Pharma giant GlaxoSmithKline (GSK -4.01%) has had an awful 2014 by any measure. Over the course of the year, this healthcare stalwart saw payers in the U.S. reject preferred reimbursement status for its next-generation respiratory drugs Anoro and Breo Ellipta, causing sales to fall well below expectations.

Then there was a bribery scandal in China, which concluded with a fine of almost $500 million and sparked allegations of bribery in a host of additional emerging markets, which triggered investigations that are expected to lead to more fines down the road.

Glaxo also threw in the towel on its highly profitable oncology unit, at least for the time being, after its cancer vaccine, MAGE-A3, failed a second pivotal late-stage trial for non-small cell lung cancer. Following this high-profile clinical flop, the company swapped its oncology unit, which had generated roughly $1.5 billion in sales in 2013, for a portion of Novartis(NVS -0.46%) vaccine unit and about $9 billion in net cash. 

Investors have steadily marched out of Glaxo in the face of this avalanche of bad news, resulting in a double-digit decline in share price:

GSK Chart

Despite the plummeting share price, though, Glaxo's management has not touched the dividend, and reportedly remains committed to maintaining the payout at $2.45 per share through 2015. As a result, Glaxo currently offers one of the richest payouts in the healthcare sector at a stately 5.72% yield. The average yield in the healthcare sector, by contrast, sits at a mere 2.22%. 

Should investors jump on this monster dividend?
Before doing so, investors should understand several issues first first. Chief among them, Glaxo has fundamentally altered its core business structure and focus going forward. According to its third-quarter earnings release, management intends to reorganize the company to reflect its renewed emphasis on vaccines and consumer healthcare.

These two units are thus expected to generate more than 40% of all revenue within the next two to three years. For comparative purposes, vaccines and consumer healthcare presently make up about 35% of total revenue. 

As part of this slight pivot away from pharmaceuticals, Glaxo is also exploring a potential IPO for a minority stake in its fast-growing HIV business, ViiV Healthcare, which it co-owns with Pfizer (PFE -0.87%) and Shionogi.

Although an IPO is not expected anytime soon, I think the idea is to have a source of funds on tap in case the company pushes deeper into the realms of vaccines and consumer healthcare, presumably by significantly increasing their research and development budgets (Glaxo's management isn't known for pursuing huge buyouts).

So is Glaxo a buy or not?
The bottom line is this: Glaxo is destined to become a smaller, less profitable company. Oncology products tend to have some of the highest margins and sales growth in the pharmaceutical industry, and you simply can't replace such a high-impact unit with vaccines and consumer healthcare products.

So while management has repeatedly stated that a dividend cut is not on the table, I question whether the company can live up to this promise. The sale of its oncology unit should provide enough cash to perhaps float the dividend next year. But once all of these broad changes are firmly in place, say by 2016, management might have little choice but to reduce the payout.

The alternative, in the face of lower profit margins and cash flows, would be to keep R&D budgets -- the lifeblood of any healthcare company -- static. If I was a shareholder, I would rather management sacrifice the dividend, for the sake of future growth.

All told, this healthcare giant might have further to fall before it hits bottom, due to its dramatic reorganization effort that centers around business areas with slower growth and lower profit margins.

 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
GSK
GSK
$34.59 (-4.01%) $-1.45
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.67 (-0.87%) $0.43
Novartis AG Stock Quote
Novartis AG
NVS
$85.28 (-0.46%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.